Table 1. Patients’ characteristics.
| Characteristics | n = 55 | % |
|---|---|---|
| Gender, male/ female | 25/ 30 | (45/ 55) |
| Median age, years (range) | 60 (33–74) | not applicable |
| ECOG PS, 0/ 1/ 2 | 37/ 17/ 1 | (67/ 31/ 2) |
| All RAS, wt/ mt | 29/ 26 | (53/ 47) |
| BRAF, wt/ mt/ unknown | 42/ 3/ 10 | (76/ 5/ 18) |
| UGT1A1, wt/ heterozygous SNP | 28/ 26 | (52/ 47) |
| Tumor location, right/ left | 15/ 40 | (27/ 73) |
| Primary resection, +/ − | 37/ 18 | (67/ 33) |
| Prior adjuvant therapy, +/ − | 6/ 49 | (11/ 89) |
| Liver metastasis, +/ − | 31/ 24 | (56/ 44) |
| Liver−limited metastasis, +/− | 7/ 48 | (13/ 87) |
| Lung metastasis, +/ − | 23/ 32 | (45/ 58) |
| Peritoneal metastasis, +/ − | 15/ 40 | (27/ 73) |
| Stage of diagnosis, II/ III/ IV | 3/ 7/ 45 | (5/ 18/ 82) |
| Antibodies, Bev/ Ram/ Cmab/ Pmab | 34/ 4/ 14/ 3 | (62/ 7/ 25/ 5) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; wt, wild type; mt, mutation; SNP, single nucleotide polymorphism; Bev, bevacizumab; Ram, ramcirumab; Cmab, cetuximab; Pmab, panitumumab.